Serine/threonine-protein kinase TBK1
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Serine/threonine-protein kinase TBK1 as ChEMBL target CHEMBL5408, mapped to UniProt Q9UHD2. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Serine/threonine-protein kinase TBK1 matters
Serine/threonine-protein kinase TBK1 is reviewed as Serine/threonine-protein kinase TBK1 (UniProt Q9UHD2); the current evidence base includes 14 approved drugs, 4275 compounds, and 431 assays, with lead potency reaching pChEMBL 10.2.
Serine/threonine-protein kinase TBK1 Sequence length is 729 aa.
Review this target as Serine/threonine-protein kinase TBK1, mapped to UniProt Q9UHD2. Sequence length is 729 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 14 approved drugs, 4275 compounds, and 431 assays for this target. The dominant activity type is IC50. CHEMBL3604928 is the current potency anchor at pChEMBL 10.2.
Use CHEMBL3604928 as the tractability anchor when discussing potency (pChEMBL 10.2).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Serine/threonine-protein kinase TBK1 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q9UHD2, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3604928
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL5743492
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL5985679
|
9.3 | IC50 | — |
|
|
No preferred name
CHEMBL6002719
|
9.3 | IC50 | — |
|
|
No preferred name
CHEMBL5742193
|
9.3 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MOMELOTINIB
CHEMBL1078178
|
2023 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
AMLEXANOX
CHEMBL1096
|
1996 |